Filing Details

Accession Number:
0001209191-21-044037
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-30 18:01:17
Reporting Period:
2021-06-28
Accepted Time:
2021-06-30 18:01:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1826457 Monte Rosa Therapeutics Inc. GLUE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1613867 Ali Behbahani 1954 Greenspring Drive
Suite 600
Timonium MD 21093
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-28 2,715,968 $0.00 2,715,968 No 4 C Indirect See Note 2
Common Stock Acquisiton 2021-06-28 3,257,328 $0.00 5,973,296 No 4 C Indirect See Note 2
Common Stock Acquisiton 2021-06-28 669,002 $0.00 6,642,298 No 4 C Indirect See Note 2
Common Stock Acquisiton 2021-06-28 1,050,000 $19.00 7,692,298 No 4 P Indirect See Note 2
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Note 2
No 4 C Indirect See Note 2
No 4 C Indirect See Note 2
No 4 P Indirect See Note 2
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-2 convertible preferred stock Disposition 2021-06-28 9,588,725 $0.00 2,715,968 $0.00
Common Stock Series B convertible preferred stock Disposition 2021-06-28 11,500,000 $0.00 3,257,328 $0.00
Common Stock Series C convertible preferred Stock Disposition 2021-06-28 2,361,912 $0.00 669,002 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
  2. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.